

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)

Index

- accessory nerve palsy 52–3
- age
 - as risk factor 4–7, 14
 - gender relationship 1–4, 14
 - at onset, prognostic significance 11–13
 - increasing incidence relationship 27–8
- age-related changes 174–7
- excitatory postsynaptic potential (EPSP) relationships 174–7
- MRI studies 198
- neuronal ageing 254–7
 - motoneuron loss as predisposition to developing ALS 257
 - overlap syndrome 254–5
 - spinal motoneurons 256–7
- Ala4Val mutation 25, 110
- alpha-amino-3-hydroxy-5-methyl-1,4-isoxazole propionic acid (AMPA) 101, 122
- AMPA receptors 188, 222–3
- alpha-internexin 76
- aluminium
 - as risk factor 16–18
 - Guamanian ALS and 22–3, 108
 - neurofilament phosphorylation and 78
- Alzheimer's disease (AD) 238–42
 - overlap syndrome in relation to neuronal ageing 254–5
- aminothiazolidine carboxylic acid 38
- amyotrophic cervical myelopathy in adolescence 46
- amyotrophic lateral sclerosis (ALS)
 - definition of 67
 - earliest descriptions of 27–9
 - see also* familial ALS; Guamanian ALS–PD complex; pathogenic mechanisms; pathology
- animal models 66–7, 96–104
 - excitatory amino acids 100–1
 - genetic and phenotypic features 96–7
 - motoneuron degeneration 1 mouse 100
 - muscle-deficient mouse 99
 - transgenic animals 101–4
 - Cu/Zn–SOD1 mutations 101–3
 - neurofilament gene transgenics 103–4
 - wasted mouse 99
 - wobbler mouse 98–9, 137
- anti-inflammatory therapy 225–6
- antiglutamate therapy 219–20
- antioxidants 215–19
 - dehydroepiandrosterone 218–19
 - Deprenyl 216–17
 - N-acetyl cysteine 217
 - vitamin E 216
- apoptosis 40, 94–5, 226, 256
- Appel ALS (AALS) Rating Scale 10, 229
- arteriovenous malformations 31
- Asp46Ala mutation 110
- Asp90Ala mutation 25–6, 110, 167
- aspartate 114, 119
 - see also* excitatory amino acids
- aspirin 225–6
- astrocytosis 87
- ataxia telangiectasia 99
- autoimmunity 132–5, 225
- axonal spheroids, *see* spheroids
- axonal transport impairment 77
- β -N-methylamino-L-alanine (BMAA) 22, 108, 115
- Babinski sign 35, 51
- basophilic inclusions 72, 83, 94
- Ben Hamida syndrome 6, 27
- Ben Hamida variants 6
- benign fasciculation 56
- benzodiazepine receptors 123
- beta-interferon 190
- beta-N-oxalylamino-L-alanine (BOAA) 37, 108, 115, 223
- Betz cells 23, 71, 73

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)*Index*

295

- bimodal passive airway pressure (BIPAP)
 - 7, 158, 232–3
- brain tumours 36
- brain-derived neurotrophic factor (BDNF)
 - 99, 137, 138, 141
 - therapeutic use 227, 231
- branched-chain amino acids (BCAAs)
 - 223–4
- bulbar onset 37, 43–4, 214
 - prognostic significance 11
- Bunina bodies 33, 72, 81–3, 94
- C-type synapses 93–4
- calbindin (CaBP) 127, 165, 188
- calcitonin gene-related peptide (CGRP)
 - 256
- calcium 215
 - Ca²⁺ channels 125–9, 225
 - blockade of 231
 - Guamanian ALS and 22, 108
- calcium/calmodulin-dependent protein
 - kinases 78
- calrectin (CR) 165
- cancer 62–3
 - see also* tumours
- carotenes 215
- carpal tunnel syndrome 45
- cassava roots 38
- cdc2 kinases 78
- cerebral blood flow (CBF) 202–3, 205
- cervical spondylotic myelopathy 31, 36, 45
- Chamorro, *see* Guamanian ALS–PD complex
- chandelier neurons 165
- Charcot–Marie–Tooth neuropathies 32
- chickling pea (*Lathyrus sativus*) 37–8, 108, 115
- cholinergic differentiation factor (CDF)
 - 139
- chromosome 21 110
- chronic inflammatory demyelinating
 - polyneuropathy (CIDP) 48, 50, 147
- ciliary neurotrophic factor (CNTF) 99, 100, 137, 139–40
 - therapeutic use 227–8, 231
- Clarke's column 70
- Clarke's nucleus 83
- clinical presentation 32, 43
 - adult-onset spinal muscular atrophies (SMAs) 39–41
 - Kennedy's syndrome 41–2
 - konzo disease 38–9
 - lathyrism 37–8
 - lower motoneuron (LMN) deficits 34–6, 39
 - patterns of clinical onset 42–64
 - cognitive impairment 58–62
 - dysarthria and bulbar onset 43–4
 - fasciculations and cramps 54–7
 - foot drop and impaired gait 51
 - hand weakness and wasting 44–5
 - monoclonal paraproteinaemia 63–4
 - monomelic amyotrophies 45–7
 - multifocal motor neuropathy with persistent conduction block (MMN) 47–51
 - neoplasm and ALS 62–3
 - painless, weak, wasted shoulder 51–2
 - respiratory failure 57–8
 - serratus anterior nerve palsy 53
 - spontaneous accessory nerve palsy 52–3
 - suprascapular nerve palsy 53–4
 - possible upper motoneuron signs (PUMNS) 35, 63
 - upper motoneuron (UMN) deficits 33, 34–7
- clinical trial design, *see* therapy
- clustering of ALS 18
- cognitive impairment 58–62, 239–40, 246
 - case reports 59–62
 - see also* dementia
- collagen changes 91
- compound muscle action potential (CMAP) 11, 160–1, 167
 - multifocal motor neuropathy with persistent conduction block 48, 147
- computed tomography (CT) 36–7
 - single photon emission computed tomography (SPECT) 202–3
- conduction block 47–8, 145–7
 - see also* multifocal motor neuropathy with persistent conduction block
- conduction studies 144–8
 - central motor conduction 166–7
- copper exposure, as risk factor 16–17
- copper/zinc-superoxide dismutase (Cu/Zn-SOD) mutations 77, 106, 114, 207, 237
 - absence in Guamanian ALS 22
 - animal studies 99, 100, 101–3
 - apoptosis and 95
 - epidemiology of 23–7
 - familial ALS 23–7, 90, 95, 106, 110–13
 - effects of aberrant SOD 111–13
- corpus callosum 197
- cortical abnormalities, imaging of 58, 192–3
- corticomotoneurons 92–3, 156, 168, 176–8
- corticomotoneuronal hypothesis of ALS 164–6, 238
- corticomotoneuronal system 163–4
- excitatory postsynaptic potential (EPSP) measurement 173–4

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)296 *Index*

- corticomotoneurons *cont.*
 inhibitory mechanism disorders 185–8
 single unit recordings, *see*
 electrophysiological studies
- cramp–fasciculation syndrome 56, 152
- cramps 31, 54–7
 multifocal motor neuropathy with
 persistent conduction block 48
- Creutzfeldt–Jakob disease (CJD) 240, 243–5, 246
- Cu/Zn–SOD mutations, *see* copper/zinc–
 superoxide dismutase mutations
- cyanohydrins 38
- Cycas circinalis* (cycad plant) 21–2, 23, 108
- cycasin 22, 108
- cyclin-dependent kinase 5 132
- cyclophosphamide 49
- dehydroepiandrosterone (DHEA) 3, 218–19
- dehydroepiandrosterone sulphate (DHEAS) 3–4, 218–19
- dementia 58–62, 239–43
 Alzheimer's disease (AD) 238–42
 overlap syndrome in relation to
 neuronal ageing 254–5
 case reports 59–62, 242–3
 disinhibition–dementia–Parkinson–
 amyotrophy complex (DDPAC)
 245–6
 in family members of ALS patients 252–4
 mild memory impairment with dementia
 246
 MRI studies 197
 neuronal changes 88
 Parkinsonism–dementia in sporadic ALS
 88–9
 progressive aphasic dementia 246
 rapidly progressive dementia 243–5
 thalamic dementia 246
- demographics, *see* epidemiology
- demyelination 85, 91
 chronic inflammatory demyelinating
 polyneuropathy (CIDP) 48, 50, 147
 MRI studies 193, 196
- Deprenyl 211, 216–17
- dextromethorphan 224–5
- diagnosis 8, 31–4
 accuracy of 64, 65
 El Escorial diagnostic criteria 8, 32, 33,
 144
see also clinical presentation;
 electrophysiological studies
- diaminopyridine (DAP) 234
- diaphragm, EMG studies 52, 57, 159–60
- disability scores 9–11
- disease progression 9–13
- disinhibition–dementia–Parkinson–
 amyotrophy complex (DDPAC)
 245–6
- DL-alpha-tocopherol, *see* vitamin E
- domoic acid 115
- dopaminergic function 206–7
- dopaminergic receptors 124
- drug delivery systems 236
- dysarthria 37, 43–4
- EAAC1 glutamate transporter 119, 219
- East Africa 38
- El Escorial diagnostic criteria 8, 32, 33,
 144
- elastin changes 92
- electrophysiological studies 145
 central motor conduction 166–7
 conduction studies 144–8
 corticomotoneuronal system 163–4
 electromyography (EMG) 144
 diaphragm 52, 159–60
 konzo disease 38
 needle EMG 33–4, 148–51
 examination of specific muscles 158–60
 fasciculations 151–7
 motor cortex excitability 167–70
 motor unit numerical estimates
 (MUNEs) 160–2
 single unit recordings using transcranial
 magnetic stimulation 171–88
 abnormalities in ALS 174–7
 age-related changes 174–7
 comparison between Ia afferent-driven
 and cortically driven EPSPs 179–82
 comparison of cortical EPSP and
 macro-EMG in ALS 183–4
 methodological issues 173–4, 177–9
 normative data 174–7
 paired stimulation studies and
 disordered inhibitory mechanisms in
 ALS 185–8
- ependymoma 44
- epidemiology 1–30
 age relationships 1–7, 27–8
 clustering 18
 Cu/Zn–SOD gene mutations 23–7
 gender relationships 1–3
 geographical distribution 9
 Guamanian ALS–PD complex 20–3
 incidence 7–8
 life expectancy 9–13
 mortality rates 7–8
 prevalence 7
see also risk factors
- excitatory amino acids 114
 alteration of receptor binding 121, 122

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)*Index*

297

- excitatory amino acids *cont.*
 altered plasma and cerebrospinal fluid levels 116–18
 animal models 100–1
 intoxication and motor system loss 115–16
 motor cortex excitability 168
 tissue contents 119
see also glutamate
- excitatory postsynaptic potentials (EPSPs) 171–3
 abnormalities in ALS 174–7
 age-related changes 174–7
 comparison between Ia afferent-driven and cortically driven EPSPs 179–82
 comparison of cortical EPSP and macro-EMG in ALS 183–4
 inhibitory mechanisms 185–8
 methodological issues 173–4, 177–8
- exercise intolerance 57
- eye movement abnormalities 34
- facial muscles 158
- familial ALS (FALS)
 case report 26
 Cu/Zn-SOD gene mutations 23–7, 90, 95, 106, 110–13
 dementia and 242
 neuronal changes 89–90
 pathogenic mechanisms 109–13
 effects of aberrant SOD 111–13
 mechanisms underlying cell death 111
- fasciculation–cramp syndrome 56, 152
- fasciculations 31, 54–7, 160, 221
 electrophysiological studies 151–7
 Kennedy's syndrome 41, 54, 56
 multifocal motor neuropathy with persistent conduction block 48, 54, 56
 origin of 152–6
 pectoralis muscle 52
- fibrillations 55, 158, 160
- fibroblast growth factors (FGFs) 140
 therapeutic use 230, 231
- flavonoids 215
- [¹⁸F] 2-fluoro-2-deoxy-D-glucose (FDG) 205
- 6-fluorodopa 206–7
- foot drop 51
- forced vital capacity (FVC) 158, 232
- free radicals 28, 215
- frontal lobe dementia 58–62, 240–2, 245
 case reports 59–62
- G37R mouse mutants 103
- Gabapentin (Neurontin) 55, 211, 221, 224
- gait impairment 51
- gamma-aminobutyric acid (GABA) 187–8
- gangliosides 48, 63, 134
- gastrocnemius muscle 46
- GD1b ganglioside 134
- gender, as risk factor 1–3, 14
- gene linkage, *see* linkage analysis
- gene therapy 236–7
- genioglossus muscle 158
- geographical distribution 9
- glial cell-derived neurotrophic factor (GDNF) 139, 140
 therapeutic use 229–30
- glial fibrillary acidic protein (GFAP) 87
- glial glutamate transporter (GLAST) 119, 219
- GLT-1 transporter 119–21, 219
- Glu100Gly mutation 25
- glutamate 87, 114
 agents acting on glutamate metabolism 223–4
 branched-chain amino acids 223–4
 Gabapentin 224
 altered plasma and cerebrospinal fluid levels 116–18
 altered transport of 119–21, 219
 antiglutamate therapy 219–20
 corticomotoneuronal system 163
 Guamanian ALS 109
 modulation of presynaptic glutamatergic mechanisms 220–2
see also excitatory amino acids
- glutathione 124, 215, 217
- glycine receptors 123
- glycogen synthase kinase 3 132
- GM1 ganglioside autoantibodies 48, 63, 134–5
- granulovacuolar degeneration 72
- growth factors, *see* pathogenic mechanisms
- Guamanian ALS–PD complex 20
 neuronal changes 89
 Parkinsonism–dementia association 249–52
 pathogenic mechanisms 107–9
 risk factors 20–3, 115
- Guillain–Barré syndrome 134, 147
- ¹H-MRS 199–202
- hand muscles 162, 163, 168
 weakness and wasting 44–5
- heavy metal exposure 16–18, 28
see also individual metals
- hereditary ALS, *see* familial ALS
- heterotopic neurons 85–7
- Hirano bodies 72
- Hirayama's disease 45–6, 65
 case reports 46

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)298 *Index*

- His46Arg mutation 25
Hodgkin's disease 63
Hokkaido, Japan 19
home ventilation 57–8
Honshu Kii peninsula, Japan 20, 22, 89, 251
human leucocyte antigen-DR (HLA-DR) 87, 88, 225
Huntington's disease 119
hyaline inclusions 72, 81, 83, 94, 103
- Ia afferent-driven EPSPs 179–82
idiopathic brachial neuritis 52
Ile113Thr mutation 25
imaging techniques 190–208
 magnetic resonance spectroscopy (MRS) 198–202
 positron emission tomography (PET) 203–7
 single photon emission computed tomography (SPECT) 202–3
 see also magnetic resonance imaging
immunoglobulins 133
 IgG 126–7, 225
immunological mechanisms 132–5
immunosuppressant therapy 225
incidence 7–8
 geographical variation 9
 Guamanian ALS 20
 see also epidemiology
indomethacin 226
industrial exposures 16–18
infraspinatus muscle 53–4
inheritance, adult-onset spinal muscular atrophies (SMAs) 39–40
 see also familial ALS
inhibitory mechanism disorders 185–8
insulin growth factors (IGF) 138–9
insulin-like growth factor (IGF-I/II) 138–9
 therapeutic use 211, 229
intercostal muscles 57, 160
interleukin-6 (IL-6) 139
International Classification of Diseases (ICD) 8
International Consortium for ALS Clinical Trials 211
interneurons 83, 165
 inhibitory interneurons 185–8, 206
internucleosomal region 95
intracellular free Ca^{2+} concentration 129, 130
intravenous immunoglobulin (IVIg) therapy 47, 49
iron 215
 as risk factor 16–18
 cortical lesions and 192
 Guamanian ALS and 22–3, 108
L-isoleucine 223–4
- Jakob–Creutzfeldt disease, *see* Creutzfeldt–Jakob disease
Japan
 Hokkaido, poliomyelitis incidence 19
 Honshu Kii peninsula 20, 22, 89, 251
juvenile ALS, *see* Ben Hamida syndrome
- Kennedy's syndrome 6, 41–2, 65, 148
 case report 42
 dysarthria and 44
 fasciculations 41, 54, 56
Kii peninsula, Honshu, Japan 20, 22, 89, 251
konzo disease 38–9
KSP repeats 77
- lactotransferrin 23
Lambert–Eaton syndrome 126, 127–8
Lamictal 211
lamotrigine 55, 156–7, 211, 220–1
lathyrism 37–8, 108
Lathyrus sativus (chickling pea) 37–8, 108, 115
latitude, incidence relationship 9
lead exposure, as risk factor 16–17
L-leucine 223–4
Lewy body-like inclusions 72, 81, 85, 102–3
life expectancy 7, 9–13
linkage analysis
 adult-onset spinal muscular atrophies (SMAs) 39–40
 familial ALS 109–10
lipofuscin accumulation 71, 73, 98, 256
liver pathology 92
lower motoneuron (LMN) deficits 33, 34–6, 39, 200–1
lung cancer 62
lymphomas 135, 225
lymphoproliferative diseases 63, 64, 135
lytico-bodig, *see* Guamanian ALS–PD complex
- macroglobulinemia 135
magnesium
 as risk factor 16
 Guamanian ALS and 22, 108
magnetic resonance imaging (MRI) 35–7, 191–8
 ALS with Parkinson's disease/dementia 197
 cortical abnormalities 58, 192–3
 effects of ageing 198
 Hirayama's disease 45–6

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)*Index*

299

- motor cortex excitability 170
- multifocal motor neuropathy with
 - persistent conduction block 47–8
- spinal cord 196–7
- subcortical white matter changes 193–6
- tongue 197–8
- magnetic resonance spectroscopy (MRS) 198–202
- male:female ratio 1–3
- manganese
 - as risk factor 16–17
 - Guamanian ALS and 22
- Mariana Islands, *see* Guamanian ALS–PD complex
- masseter 158
- mercury exposure, as risk factor 16
- Mestion 234
- metal exposure, *see* heavy metal exposure
- methylazoxymethanol β -D-glucoside 22
- microglial activation 87–8, 225
- micturition difficulty 26
- mitogen-activated protein kinase (MAPK) 132
- MO-1 antigen 124
- monoamine oxidase-B (MOA-B) inhibitor 216–17
- monoclonal paraproteinaemia 63–4
- monomelic amyotrophies 45–7
 - case reports 46
- mortality rates 7–8
- motoneuron degeneration 1 mouse model 100
- motoneuron diseases (MND) 8
- motor cortex excitability 167–70
- motor evoked potential (MEP) studies 38, 163, 166–8
- motor neuropathy with persistent conduction block, *see* multifocal motor neuropathy with persistent conduction block
- motor unit numerical estimates (MUNEs) 160–2
- motor unit potentials (MUPs) 148–51, 154–7
 - macro-MUPs 183
 - repetitive discharges 157
- mouse models, *see* animal models
- Mucomyst 235
- mucus, thick 234–5
- multifocal motor neuropathy with
 - persistent conduction block (MMN) 47–51, 63, 65
 - case reports 50, 91
 - conduction studies 144–8
 - fasciculations 48, 54, 56
 - immunological mechanisms 134–5
- multiple cerebral infarcts 36–7
- multiple myeloma 135
- multiple sclerosis (MS) 9, 36, 147, 190
- muscarinic cholinergic receptors 123
- muscle wasting 31, 35, 91
 - hands 44–5
 - shoulder 51–2
 - see also* nerve palsies; *specific muscles*
- muscle-deficient mouse model 99
- myasthenia gravis 44
- N-acetyl acetate (NA) 199
 - NA/Cr ratios 199–201
- N-acetyl aspartate (NAA) 119, 199–202
- N-acetyl aspartyl-glutamate (NAAG) 119, 199, 201–2
- N-acetyl-L-cysteine (NAC) 99, 217–18
- N-isopropyl-p-¹²³I-amphetamine (¹²³I-IMP) 202
- N-methyl-D-aspartate (NMDA) 101
 - NMDA receptor antagonists 224–5
 - NMDA receptors 79, 122, 132, 182, 188
- needle EMG 33–4, 148–51
 - diaphragm 52, 159–60
 - specific muscles 158–60
- neoplasms 62–3
- nerve growth factor (NGF) 137, 227
- nerve palsies 52–4
 - accessory nerve 52–3
 - serratus anterior nerve 53
 - suprascapular nerve 53–4
- neuralgic amyotrophy 52–3
- neurodegenerative overlap syndrome 255
- neurofilaments
 - accumulation of 66, 73–5, 165
 - animal models 102, 103–4
 - nitration of 79–80
 - phosphorylation of 78–9, 132
- neuronal apoptosis inhibitory protein (NAIP) gene 40, 95
- neuronal changes, *see* pathology
- Neurontin (Gabapentin) 55, 211, 221, 224
- neuroprotective therapy, *see* therapy
- neurotransmitter receptor involvement 122–4
- neurotrophins 136–7, 227
 - brain-derived neurotrophic factor 137, 227
 - nerve growth factor 137, 227
 - neurotrophin-3 (NT-3) 100, 137–8, 141, 227
 - neurotrophin-4/5 (NT-4/5) 138, 227
 - therapeutic use 227
- New Guinea 20, 22, 251
- Nissl bodies 93–4, 256
- nitration, of neurofilaments 79–80
- nitric oxide synthase (NOS) 80
- non-Hodgkin's lymphoma 63

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)300 *Index*

- non-NMDA receptor-mediated neurotoxicity 222–3
- non-steroidal anti-inflammatory drugs (NSAIDs) 225–6
- nutritional care 233–4
- occupational exposures 16–18
- odds ratio 15–16
- oestrogens 14
- Onuf's nucleus 33, 164
- ophthalmoplegia 34
- p75 receptor 136
- paired stimulation studies 185–8
 - normal subjects 185–7
 - patients with ALS 187–8
- pancreatic cancer 63
- paraneoplastic motoneuron disease 63
- paraproteinaemia 63–4, 225
- Parkinson's disease (PD) 238–9
 - ALS and 248–9
 - disinhibition–dementia–Parkinson–amyotrophy complex (DDPAC) 245–6
 - in family members of ALS families 252–4
 - MRI studies 197
 - overlap syndrome in relation to neuronal ageing 254–5
 - Parkinsonism, dementia and ALS 88–9, 249–52
 - subclinical Parkinsonism 247–8
- parvalbumin (PV) 127, 165, 188
- pathogenic mechanisms
 - altered protein kinase activity 129–32
 - cell surface receptor involvement 114, 124
 - excitotoxicity 114–22
 - altered EAA receptor binding 121, 122
 - altered glutamate transport 119–21
 - altered plasma and cerebrospinal fluid EAAs 116–18
 - EAA intoxication and motor system loss 115–16
 - therapeutic trials 121–2
 - tissue contents of EAAs 119
- familial ALS 109–13
 - effects of aberrant SOD 111–13
 - mechanisms underlying cell death 111
- growth factor involvement 135–41
 - ciliary neurotrophic factor 139–40
 - fibroblast growth factors 140
 - glial cell-derived neurotrophic factor 139
 - insulin growth factors 138–9
 - neurotrophins 136–7
 - transforming growth factor- β 141
- Guamanian ALS 107–9
- immunological mechanisms 132–5
- increased intracellular free Ca^{2+} concentration 129
- ionic channel involvement 125–9
 - Ca^{2+} channels 125–9
- neurotransmitter receptor involvement 122–4
- pathology 68–95
 - anatomical issues 92–5
 - apoptosis 94–5
 - target dependence of motoneuron ultrastructure 93–4
 - trans-synaptic changes 92–3
 - cellular inclusions 72
 - microscopic findings 68–9
 - neuronal changes frequently seen 73–85
 - basophilic inclusions 83
 - Bunina bodies 81–3
 - hyaline inclusions 83
 - interneuron involvement 83–4
 - neurofilament accumulation 73–5
 - neurofilament nitration 79–80
 - neurofilament phosphorylation 78–9
 - spheroids 75–7
 - tract degeneration 84–5
 - ubiquitinated inclusions 80–1
 - neuronal changes in specific related conditions 88–90
 - ALS with dementia 88
 - ALS with prolonged survival 90
 - familial ALS 89–90
 - Guamanian ALS 89
 - Parkinsonism–dementia in sporadic ALS 88–9
- neuronal changes invariably present 69–73
 - neuronal loss 69–70
 - senescent changes 71–3
 - simple atrophy 70–1
- pathology outside central nervous system 90–2
 - liver 92
 - muscle 91
 - skin 91–2
 - spinal nerve roots and peripheral nerves 90–1
- uncommon pathological features 85–8
 - astrocytosis 87
 - heterotopic neurons 85–7
 - Lewy bodies 85
 - microglial activation 87–8
- see also* animal models
- pectoralis muscle 52
- percutaneous endoscopically placed gastrostomy (PEG) 7, 233–4
- pericapillary bodies 72

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)*Index*

301

- peripheral nerves 90–1
- peripherin 76
- peristimulus time histograms (PSTHs) 171–3, 177–8
 - construction methodology 173–4
 - paired stimulation studies 185, 187
- phosphatidylinositol-3-hydroxy kinase 131
- phosphorylation, of neurofilaments 78–9, 132
- Pick's disease 240–2
- plexopathies 45, 51
- poliomyelitis 85, 257
 - as risk factor 19
 - post-poliomyelitis syndrome 205, 257
- pontine gliomas 85
- positron emission tomography (PET) 203–7, 238, 242
 - cortical abnormalities 58
 - motor cortex excitability 170
- possible upper motoneuron signs (PUMNS) 35, 63
- MRS studies 199–201
- post-polio progressive muscular atrophy (PPMA) 257
- prednisone 234
- presentation, *see* clinical presentation
- prevalence 7
 - see also* epidemiology
- primary lateral sclerosis (PLS) 35–6
 - case report 35–6
- prion proteins 243
- prognosis 9–13
- programmed cell death, *see* apoptosis
- progression of disease 9–13
- progressive bulbar palsy 67, 194
- progressive lumbosacral plexopathy 51
- progressive motor neuropathy mouse model 99–100
- progressive muscular atrophy (PMA) 6, 35, 67, 166
 - post-polio progressive muscular atrophy (PPMA) 257
 - progressive spinal muscular atrophy (PSMA)
 - MRS studies 200–1
 - PET studies 205
- protein kinases 78, 122
 - altered activity in ALS 129–32
 - protein kinase A (PKA) 78
 - protein kinase C (PKC) 78, 130–2
 - protein kinase M (PKM) 130
- protein phosphatases 78–9, 131–2
- proton-magnetic resonance spectroscopy (¹H-MRS) 199–202
- pugilistic encephalopathy 19
- pyramidal neurons 69, 71, 85, 90, 206
 - age-related changes 176–7
- pyridostigmine 234
- radiculopathies 56
- rectus abdominus muscle 158
- rehabilitative measures 234
- repetitive discharges 157
- respiratory care 231–3
- respiratory failure 57–8
- Rilutek, *see* riluzole
- riluzole 7, 121, 220, 221–2
 - fasciculations and 55, 156–7, 221
 - trials 210–11
- risk factors 14–23
 - age 4–7, 14, 27–8
 - gender relationship 1–3, 14
- case control studies 15
- cohort studies 14–15
- cross-sectional prevalence studies 14
- Guamanian ALS–PD complex 20–3
- heavy metal exposure 16–18, 28
- poliomyelitis 19
- trauma 18–19
- Rota, *see* Guamanian ALS–PD complex
- salivation, excess 234–5
- Sanofi-SR57746A 211, 230
- scapula 53
- selegiline 211, 216–17
- selenium
 - as risk factor 16–18
 - Guamanian ALS and 22
- senescent neuronal changes 71–3
- sensory nerve action potentials (SNAPs), Kennedy's syndrome 41, 56, 148
- serotonin receptors 124
- serratus anterior nerve palsy 53
- shoulder weakness and wasting 51–2
 - accessory nerve palsy and 52–3
 - serratus anterior nerve palsy and 53
 - suprascapular nerve palsy and 53–4
- Sickness Impact Profile (SIP) 214
- single photon emission computed tomography (SPECT) 202–3, 242
- skin pathology 91–2
- soleus muscle 181–2
- spheroids 33, 72, 75–7, 165
- spinal cord
 - MRI studies 196–7
 - tumour 31
- spinal muscular atrophies (SMAs) 87, 169
 - adult-onset 39–41
 - progressive SMA (PSMA)
 - MRS studies 200–1
 - PET studies 205
 - see also* Kennedy's syndrome
- spinal nerve roots 90–1

Cambridge University Press

978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice

Andrew Eisen and Charles Krieger

Index

[More information](#)302 *Index*

- SR57746A 211, 230
 sternomastoid muscle 158
 stress-activated kinases 132
 substance P receptors 123
 superoxide dismutase (SOD), *see* copper/
 zinc-superoxide dismutase
 mutations
 suprascapular nerve palsy 53–4
 supraspinatus muscle 53–4
 survival, length of 9–13
 survival motoneuron gene (SMN) 40
 syringomyelia 31, 44
- Tanzania 38
 tau protein kinases 78
 taurine 109, 215
 telomerase 237
 thenar muscles 162
 wasting 45
 theophylline 231
 therapy 209–37
 agents acting on glutamate metabolism
 223–4
 branched-chain amino acids 223–4
 Gabapentin 224
 agents acting on glutamate receptors
 224–5
 antiglutamate therapy 219–20
 calcium channel blockade 231
 future directions 235–7
 gene therapy 236–7
 new drug delivery systems 236
 immunosuppressant therapy 225
 modulation of presynaptic glutamatergic
 mechanisms 220–2
 neuroprotective therapy 215–19
 dehydroepiandrosterone 218–19
 Deprenyl 216–17
 N-acetyl cysteine 217
 vitamin E 216
 neurotrophic factors 226–31
 ciliary neurotrophic factor 227–8
 combination therapy 230–1
 fibroblast growth factors 230
 glial cell-derived neurotrophic factor
 229–30
 insulin-like growth factors 229
 neurotrophins 227
 Sanofi-SR57746A 230
 non-steroidal anti-inflammatory drugs
 (NSAIDs) 225–6
 symptomatic measures 231–5
 excessive salivation and thick mucus
 234–5
 nutritional care 233–4
 rehabilitative measures 234
 respiratory care 231–3
 therapeutic strategies 210
 trial design 210–15
 placebo controls 210–12
 L-threonine 224
 thyroid releasing hormone receptors 123–4
 tongue 158
 fasciculation 55
 fibrillation 55
 MRI imaging 197–8
 tract degeneration 84–5
 trans-synaptic changes 92–3
 transcranial magnetic stimulation (TMS)
 163–7
 single unit recordings, *see*
 electrophysiological studies
 transforming growth factor- β (TGF- β)
 139, 140, 141
 transgenic animals, *see* animal models
 transverse myelopathy 85
 trapezius muscle 52–3
 trauma, as risk factor 18–19
 treatment, *see* therapy
 trinucleotide repeated sequences,
 Kennedy's syndrome 41
 tubular particles 72
 Tufts Quantitative Neuromuscular Exam
 (TQNE) 9, 10, 213, 231
 tumours 62–3
 brain 36
 lymphomas 135, 225
 pontine gliomas 85
 spinal cord 31
 Tunisia 6, 27
 Turkey 6
 tyrosine kinase receptor (Trk) family 136–
 7, 138
- ubiquitin-immunoreactive intraneuronal
 inclusion bodies 33, 66, 80–1
 upper motoneuron (UMN) deficits 33, 34–7
 uric acid 215
- L-valine 223–4
 ventilatory support 232–3
 home ventilation 57–8
 ventral horn neurons 69, 83, 197
 verapamil 231
 vitamin C 215
 vitamin E 211, 215, 216
- walking difficulties 51
 wasted mouse model 99
 wasting, *see* muscle wasting
 weakness 31, 35
 hands 44–5
 shoulder 51–2
 see also nerve palsies

Cambridge University Press
978-0-521-03426-5 - Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice
Andrew Eisen and Charles Krieger
Index
[More information](#)

Index 303

white matter changes, imaging studies 193–6	xanthine oxidase 129
Wisconsin Card Sorting Test 58	young-onset disease 6, 39
wobbler mouse model 98–9, 137	Zaire 38
X-linked progressive bulbar spinal muscular atrophy, <i>see</i> Kennedy’s syndrome	zinc
	as risk factor 17, 18
	Guamanian ALS and 22